Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021
- Lee JJ
1 - Choe YJ2
- Jeong H3
- Kim M3
- Kim S3
- Yoo H3
- Park K4
- Kim C4
- Choi S4
- Sim J5
- Park Y5
- Huh IS5
- Hong G5
- Kim MY6
- Song JS6
- Lee J6
- Kim EJ1
- Rhee JE1
- Kim IH1
- Gwack J1
- Kim J1
- Jeon JH1
- Lee WG1
- Jeong S1
- Kim J1
- Bae B1
- Kim JE7
- Kim H7
- Lee HY1
- Lee SE1
- Kim JM1
- Park H1
- Yu M1
- Choi J1
- Kim J1
- Lee H1
- Jang EJ1
- Lim D1
- Lee S1
- Park YJ1
- Affiliations
-
- 1Korea Disease Control and Prevention Agency, Cheongju, Korea
- 2Korea University Anam Hospital, Seoul, Korea
- 3Incheon Metropolitan Government, Incheon, Korea
- 4Gyeonggi-do Infectious Disease Control Center, Suwon, Korea
- 5Seoul Metropolitan Government, Seoul, Korea
- 6Capital Regional Center for Disease Control and Prevention, Seoul, Korea
- 7Incheon Airport National Quarantine Station, Incheon, Korea
- KMID: 2523565
- DOI: http://doi.org/10.3346/jkms.2021.36.e346
Abstract
- In November 2021, 14 international travel-related severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant of concern (VOC) patients were detected in South Korea. Epidemiologic investigation revealed community transmission of the omicron VOC. A total of 80 SARS-CoV-2 omicron VOC-positive patients were identified until December 10, 2021 and 66 of them reported no relation to the international travel. There may be more transmissions with this VOC in Korea than reported.
Keyword
Figure
-
Fig. 1 Chronological distribution of SARS-CoV-2 B.1.1.529 (omicron) variant of concern cases. (A) Epidemic curve of reported confirmed cases (n = 80). (B) Patterns of community transmission.
Cited by 5 articles
-
Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
Min-Kyung Kim, Bora Lee, Youn Young Choi, Jihye Um, Kyung-Shin Lee, Ho Kyung Sung, Yeonjae Kim, Jun-Sun Park, Myungsun Lee, Hee-Chang Jang, Ji Hwan Bang, Ki-hyun Chung, Jaehyun Jeon
J Korean Med Sci. 2022;37(3):e31. doi: 10.3346/jkms.2022.37.e31.Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
Susin Park, Nam Kyung Je, Dong Wan Kim, Miran Park, Jeonghun Heo
J Korean Med Sci. 2022;37(13):e102. doi: 10.3346/jkms.2022.37.e102.Multi-Faceted Analysis of COVID-19 Epidemic in Korea Considering Omicron Variant: Mathematical Modeling-Based Study
Youngsuk Ko, Victoria May Mendoza, Renier Mendoza, Yubin Seo, Jacob Lee, Jonggul Lee, Donghyok Kwon, Eunok Jung
J Korean Med Sci. 2022;37(26):e209. doi: 10.3346/jkms.2022.37.e209.Shift in Clinical Epidemiology of Human Parainfluenza Virus Type 3 and Respiratory Syncytial Virus B Infections in Korean Children Before and During the COVID-19 Pandemic: A Multicenter Retrospective Study
Ye Kyung Kim, Seung Ha Song, Bin Ahn, Joon Kee Lee, Jae Hong Choi, Soo-Han Choi, Ki Wook Yun, Eun Hwa Choi
J Korean Med Sci. 2022;37(28):e215. doi: 10.3346/jkms.2022.37.e215.Perioperative Respiratory-Adverse Events Following General Anesthesia Among Pediatric Patients After COVID-19
Jung-Bin Park, Jin Young Sohn, Pyoyoon Kang, Sang-Hwan Ji, Eun-Hee Kim, Ji-Hyun Lee, Jin-Tae Kim, Hee-Soo Kim, Young-Eun Jang
J Korean Med Sci. 2023;38(47):e349. doi: 10.3346/jkms.2023.38.e349.
Reference
-
1. World Health Organization. Tracking SARS-CoV-2 variants. Updated 2021. Accessed December 13, 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants .2. Park YJ, Choe YJ, Park O, Park SY, Kim YM, Kim J, et al. Contact tracing during coronavirus disease outbreak, South Korea, 2020. Emerg Infect Dis. 2020; 26(10):2465–2468. PMID: 32673193.
Article3. Gu H, Krishnan P, Ng DY, Chang LD, Liu GY, Cheng SS, et al. Probable transmission of SARS-CoV-2 Omicron variant in Quarantine Hotel, Hong Kong, China, November 2021. Emerg Infect Dis. Forthcoming. 2021; DOI: 10.3201/eid2802.212422.
Article4. Callaway E, Ledford H. How bad is Omicron? What scientists know so far. Nature. 2021; 600(7888):197–199. PMID: 34857948.
Article5. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant – United States, December 1–8, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(50):1731–1734. PMID: 34914670.6. Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021; 600(7888):204–207. PMID: 34876665.
Article7. Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. ArXiv. December. 1. 2021; https://arxiv.org/abs/2112.01318 .
Article
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask
- Widespread Household Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant from Children, South Korea, 2022
- Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies
- Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
- Household secondary attack rates and risk factors during periods of SARS-CoV-2 Delta and Omicron variant predominance in the Republic of Korea
